

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 October 2023 (19.10.2023)



(10) International Publication Number
WO 2023/201270 A3

(51) International Patent Classification:

C12N 15/11 (2006.01) C12N 15/88 (2006.01)
C12N 15/113 (2010.01) C12N 9/22 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/065685

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

12 April 2023 (12.04.2023)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/330,695 13 April 2022 (13.04.2022) US
63/332,173 18 April 2022 (18.04.2022) US

(88) Date of publication of the international search report:

28 December 2023 (28.12.2023)

(71) Applicant: **CARIBOU BIOSCIENCES, INC.** [US/US];
2929 7th Street, Suite 105, Berkeley, CA 94710 (US).

(72) Inventors: **DONOHUE, Paul Daniel**; Caribou Bio-
sciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA
94710 (US). **KANNER, Steven B.**; Caribou Biosciences,
Inc., 2929 7th Street, Suite 105, Berkeley, CA 94710 (US).
MUNOZ-HOWELL, Antonio; Caribou Biosciences, Inc.,
2929 7th Street, Suite 105, Berkeley, CA 94710 (US).
RAHDAR, Meghdad; Caribou Biosciences, Inc., 2929 7th
Street, Suite 105, Berkeley, CA 94710 (US).

(74) Agent: **ZIMMERMAN, Olga**; Director, I.p., Caribou Bio-
sciences, Inc., 2929 7th Street, Suite 105, Berkeley, CA
94710 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: THERAPEUTIC APPLICATIONS OF CRISPR TYPE V SYSTEMS

(57) Abstract: The present disclosure provides methods and compositions for therapeutic use, where the methods and compositions include Type V CRISPR systems with RNA guides contain ribonucleotide bases and at least one deoxyribonucleotide base. The Type V CRISPR systems are used to perform therapeutic, genome editing in somatic cells, induced pluripotency stem cells (iPSCs) and germline or embryonic cells of animals for xenotransplantation of organs and tissues

WO 2023/201270 A3